255 related articles for article (PubMed ID: 18535816)
1. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.
Vergès B; Florentin E; Baillot-Rudoni S; Monier S; Petit JM; Rageot D; Gambert P; Duvillard L
Diabetologia; 2008 Aug; 51(8):1382-90. PubMed ID: 18535816
[TBL] [Abstract][Full Text] [Related]
2. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM.
Taskinen MR; Packard CJ; Shepherd J
Diabetes; 1990 Sep; 39(9):1017-27. PubMed ID: 2200727
[TBL] [Abstract][Full Text] [Related]
3. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.
Gaw A; Packard CJ; Lindsay GM; Griffin BA; Caslake MJ; Lorimer AR; Shepherd J
J Lipid Res; 1995 Jan; 36(1):158-71. PubMed ID: 7706941
[TBL] [Abstract][Full Text] [Related]
4. Development and application of a multicompartmental model to study very low density lipoprotein subfraction metabolism.
Packard CJ; Gaw A; Demant T; Shepherd J
J Lipid Res; 1995 Jan; 36(1):172-87. PubMed ID: 7706942
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of apoB-100-containing lipoproteins in familial hyperchylomicronemia.
Demant T; Gaw A; Watts GF; Durrington P; Buckley B; Imrie CW; Wilson C; Packard CJ; Shepherd J
J Lipid Res; 1993 Jan; 34(1):147-56. PubMed ID: 8445339
[TBL] [Abstract][Full Text] [Related]
6. Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy.
Taskinen MR; Matikainen N; Björnson E; Söderlund S; Inkeri J; Hakkarainen A; Parviainen H; Sihlbom C; Thorsell A; Andersson L; Adiels M; Packard CJ; Borén J
Diabetologia; 2023 Dec; 66(12):2307-2319. PubMed ID: 37775612
[TBL] [Abstract][Full Text] [Related]
7. Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome.
Ooi EM; Watts GF; Chan DC; Chen MM; Nestel PJ; Sviridov D; Barrett PH
Diabetes Care; 2008 Aug; 31(8):1656-61. PubMed ID: 18509206
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes.
Vergès B; Florentin E; Baillot-Rudoni S; Petit JM; Brindisi MC; Pais de Barros JP; Lagrost L; Gambert P; Duvillard L
J Lipid Res; 2009 Jun; 50(6):1209-15. PubMed ID: 19168444
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome.
Ooi EM; Barrett PH; Chan DC; Nestel PJ; Watts GF
Atherosclerosis; 2008 Mar; 197(1):139-46. PubMed ID: 17416370
[TBL] [Abstract][Full Text] [Related]
10. Effects of simvastatin on apoB metabolism and LDL subfraction distribution.
Gaw A; Packard CJ; Murray EF; Lindsay GM; Griffin BA; Caslake MJ; Vallance BD; Lorimer AR; Shepherd J
Arterioscler Thromb; 1993 Feb; 13(2):170-89. PubMed ID: 8427854
[TBL] [Abstract][Full Text] [Related]
11. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
Taskinen MR; Björnson E; Kahri J; Söderlund S; Matikainen N; Porthan K; Ainola M; Hakkarainen A; Lundbom N; Fermanelli V; Fuchs J; Thorsell A; Kronenberg F; Andersson L; Adiels M; Packard CJ; Borén J
Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):962-975. PubMed ID: 33356392
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
13. Model development to describe the heterogeneous kinetics of apolipoprotein B and triglyceride in hypertriglyceridemic subjects.
Barrett PH; Baker N; Nestel PJ
J Lipid Res; 1991 May; 32(5):743-62. PubMed ID: 2072038
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG
J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
[TBL] [Abstract][Full Text] [Related]
15. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
Aguilar-Salinas CA; Barrett PH; Kelber J; Delmez J; Schonfeld G
J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
[TBL] [Abstract][Full Text] [Related]
16. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
[TBL] [Abstract][Full Text] [Related]
17. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419
[TBL] [Abstract][Full Text] [Related]
18. New dimension of statin action on ApoB atherogenicity.
Chapman MJ; Caslake M; Packard C; McTaggart F
Clin Cardiol; 2003 Jan; 26(1 Suppl 1):I7-10. PubMed ID: 12539816
[TBL] [Abstract][Full Text] [Related]
19. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
20. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
